

PHARMACY GNIPST BULLETIN

Volume-4, Issue-2



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

Contents

01 Message from Director and Principal

02 Recent Researches

03 New Drug Approvals

04 Clinical Trial News

05 Disease Outbreak News

06 Campus News

07 Special Page and Game time



Na¹¹
Au⁷⁸

GNIPST BULLETIN 2026





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and best wishes to all our students, faculty members, staff, alumni, and well-wishers on the auspicious occasion of National Science Day.

National Science Day is celebrated to honor the remarkable contributions of Indian scientists and to commemorate the discovery of the Raman Effect by Sir C. V. Raman.

This day serves as a reminder of the transformative power of science in shaping our world and improving the quality of life for humanity.

At GNIPST, we are committed to fostering a culture of scientific inquiry, research excellence, and innovation. We aim to equip our students with strong scientific knowledge, analytical skills, and ethical values, enabling them to become competent professionals and responsible contributors to the scientific community.

On this significant day, let us inspire our students to question, explore, and innovate fearlessly. As educators and mentors, it is our responsibility to nurture their scientific temperament and guide them toward discoveries that can benefit society and the nation.

Let us celebrate National Science Day by reaffirming our dedication to advancing knowledge, promoting research, and building a future driven by science and innovation.

Warm wishes to all on National Science Day.

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and heartfelt best wishes to our students, faculty members, staff, alumni, and valued partners on the auspicious occasion of National Science Day. National Science Day is celebrated to commemorate the groundbreaking discovery of the Raman Effect by Sir C. V. Raman and to recognize the immense contributions of the scientific community in advancing knowledge and improving human life. This day highlights the importance of science as a driving force for innovation, development, and societal progress.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that scientific education plays a pivotal role in national development. Since our inception in 2005, GNIPST has evolved into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), accredited by NAAC and NBA, and ranked 85th in NIRF 2025. Our commitment remains steadfast in promoting academic excellence, research innovation, and ethical practices.

On this significant occasion, let us reaffirm our dedication to fostering a scientific temper among our students and creating an environment that encourages research, innovation, and lifelong learning. As educators and mentors, it is our responsibility to inspire young minds to pursue knowledge with passion and integrity.

May this National Science Day motivate our students to contribute meaningfully to scientific advancements and serve society with knowledge, responsibility, and innovation.

Warm wishes to all on National Science Day.

Prof. (Dr.) Lopamudra Datta



Na¹¹
Au⁷⁹

GNIPST BULLETIN 2026





RECENT RESEARCHES



WMulti-country outbreak of cholera, epidemiological update #33 -27 January 2026

MORE INFO

www.who.int/

From 1 January to 28 December 2025, a cumulative total of 614 828 cholera cases and 7598 deaths were reported from 33 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the Western Pacific Region. No cases were reported from the European Region during this period.

In December 2025 (epidemiological weeks 49 to 52) a total of 17 327 new cholera and acute watery diarrhoea (AWD) cases were reported from 16 countries across three WHO regions, showing a 25% decrease from November. In this period, 137 cholera-related deaths were reported globally, a 16% decrease from the previous month.

Cambodia and Thailand have long disputed several non-demarcated areas along their shared 800-kilometre land border.

Tensions escalated in May 2025 following a fatal clash between soldiers, sparking a diplomatic crisis and increased military buildup on both sides. On 15 June, Cambodia appealed to the International Court of Justice (ICJ) for resolution. The situation worsened after two landmine incidents injured Thai soldiers in July, with mutual accusations of provocation leading to intensified skirmishes and culminating in a major military confrontation on 24 July.

An upsurge of mpox (formerly known as monkeypox) in the Democratic Republic of the Congo and its spread to neighbouring countries was declared a public health emergency of international concern on 14 August 2024.

Mpox is a viral disease caused by an orthopoxvirus. It spreads mainly through close contact with someone who has mpox, causing a painful rash, enlarged lymph nodes, and fever. It can make people very sick and leave scars.

A global outbreak of mpox began in May 2022 and continues to this day. In recent months, cases have been increasing in the Democratic Republic of the Congo. A new strain of the virus, called Clade Ib, is causing outbreaks in previously unaffected areas of the country and has spread to countries that had not previously reported mpox.

WHO is working with affected countries and partners to contain these outbreaks.

Public Health Situation Analysis - Cambodia - Thailand border conflict

MORE INFO

www.who.int/

Mpox outbreak

MORE INFO

www.who.int/

Na¹¹
Au⁷⁸

GNIPST BULLETIN 2026



FDA

NEW DRUG APPROVALS

Zycubo (copper histidine)
Injection – formerly CUTX-
101

- Date of Approval: January 12, 2026
- Company: Sentyln Therapeutics, Inc.
- Treatment for: Menkes Disease



Yuvezzi (brimonidine tartrate and carbachol) Ophthalmic Solution – formerly Brimochol PF

- Date of Approval: January 28, 2026
- Company: Tenpoint Therapeutics, Ltd.
- Treatment for: Presbyopia



Adquey (difamilast) Ointment

- Date of Approval: February 12, 2026
- Company: Acrotech Biopharma Inc.
- Treatment for: Atopic Dermatitis



Bysanti (milsaperidone)
Tablets

- Date of Approval: February 20, 2026
- Company: Vanda Pharmaceuticals Inc.
- Treatment for: Schizophrenia, Bipolar Disorder



Loargys (pegzilarginase-nbln)
Injection

- Date of Approval: February 23, 2026
- Company: Immedica Pharma
- Treatment for: Arginase 1 Deficiency



Yuviwel (navepegritide)
Lyophilized Powder for Injection
– formerly TransCon CNP

- Date of Approval: February 27, 2026
- Company: Ascendis Pharma A/S
- Treatment for: Achondroplasia



lootyde (icotrokinra hydrochloride) Tablets

- Date of Approval: March 17, 2026
- Company: Johnson & Johnson
- Treatment for: Plaque Psoriasis



<https://www.drugs.com/newdrugs-archive/2025.html>



CLINICAL TRIAL NEWS



01.

GSK Announces Positive Results from B-Well 1 and B-Well 2 Phase III trials for Bepirovirsen, a Potential First-in-Class Treatment for Chronic Hepatitis B

London, UK -- 07 January 2026 GSK plc (LSE/NYSE: GSK) today announced positive results from its two pivotal phase III trials, B-Well 1 [NCT05630807] and B-Well 2 [NCT 05630820], evaluating bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB) in over 1,800 patients from 29 countries.

02.

Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update

WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and its business.

03.

Valneva Announces Voluntarily Withdrawal of Ixchiq (chikungunya vaccine, live) BLA in the U.S.

Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, Ixchiq, in the United States, following suspension of the license by the U.S. Food and Drug Administration (FDA) in August 2025.

04.

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With Keytruda (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma

CAMBRIDGE, Mass. and RAHWAY, N.J. / ACCESS Newswire / Jan. 20, 2026 / Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy (INT),

05.

Opna Bio Announces Orphan Drug Designation Granted to OPN-2853 (Zavabresib) for the Treatment of Myelofibrosis

SOUTH SAN FRANCISCO, CA – January 21, 2026 – Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET) small molecule inhibitor, has been granted Orphan Drug Designation (ODD) for the treatment of myelofibrosis (MF) by the U.S. Food and Drug Administration (FDA).

06.

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial of Nexiguran Ziclumeran in ATTRv-PN

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

07.

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

CAMBRIDGE, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2). CLE is a chronic autoimmune disease affecting the skin that currently has no targeted treatments.

MORE INFORMATION ➔

https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html

DISEASE OUTBREAK NEWS (DON5)

January 2026


Marburg virus disease - Ethiopia

26 January 2026

Situation at a glance

On 26 January 2026, the Ministry of Health of Ethiopia declared the end of the Marburg virus disease (MVD) outbreak. This declaration came after two consecutive incubation periods (a total of 42 days) since the last person confirmed with MVD died and was given a safe and dignified burial, in accordance with WHO recommendations on 14 December 2025. As of 25 January 2026, a cumulative total of 19 cases, including 14 confirmed (including nine deaths) and five probable cases (all deaths), were reported. A total of 857 contacts listed for monitoring all had completed their 21-day follow-up as of 25 January 2026. WHO, through its country office and partners, provided technical, operational and financial support to the government to contain this outbreak.

MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON592>



Nipah virus infection - India

30 January 2026

Situation at a glance


On 26 January 2026, the National IHR Focal Point for India notified WHO of two laboratory-confirmed cases of Nipah virus (NiV) infection in West Bengal State. Both are healthcare workers at the same private hospital in Barasat (North 24 Parganas district). NiV infection was confirmed at the National Institute of Virology in Pune on 13 January. One case remains on mechanical ventilation as of 21 January, the other case experienced severe neurological illness but has since improved. Authorities have identified and tested over 190 contacts, who all tested negative for NiV with support from a mobile BSL-3 laboratory deployed by the National Institute of Virology, Pune. No further cases have been detected to date. This event represents the third NiV infection outbreak reported in West Bengal (previous outbreaks reported in Siliguri in 2001 and Nadia in 2007). Enhanced surveillance and infection prevention and control (IPC) measures are in place while investigations into the source of exposure are ongoing. NiV infection is a serious but rare zoonotic disease transmitted to humans through infected animals (such as bats), or food contaminated with saliva, urine, and excreta of infected animals. It can also be transmitted directly from person to person through close contact with an infected person. There are currently no licensed medicines or vaccines for NiV infection, however early supportive care can improve survival. WHO assesses the risk posed by Nipah to be moderate at the sub-national level, and low at the national, the regional and global levels.



MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>



CAMPUS NEWS





1. **International Conference:** Guru Nanak Institute of Pharmaceutical Science & Technology (GNIPST), organized a two day International Conference on “Frontiers in Medical, Pharmaceutical and Allied Sciences: Translating Innovation into Impact” on February 26–27, 2026. Day 1 at Taj City Centre, Kolkata, united experts from Sri Lanka, Malaysia, West Bengal & Jharkhand and Day 2 at Guru Nanak Institute of Pharmaceutical Science & Technology (GNIPST), Sodepur. We are delighted to have the International Journal of Applied Pharmaceutics (Scopus Indexed, CiteScore 2.1) as our Publication Partner, in association with Innovare Academic Sciences Pvt. Ltd.



2. **World Day of Social Justice:** On the occasion of World Day of Social Justice, the Debate & Extempore Club of GNIPST proudly organized a thought-provoking Group Discussion Session on “Justice Through Dialogue” and the Theme was on Human Rights, Equality, and Social Transformation.



**MORE
DETAILS**



NATIONAL SCIENCE DAY

2026

National Science Day is celebrated every year on 28th February in India to mark the discovery of the Raman Effect by Sir C. V. Raman in 1928. This day emphasizes the vital role of science in shaping modern society and improving quality of life. In 2026, the celebration highlights sustainable development, innovation, and technological progress as key drivers of national growth. Educational institutions and scientific organizations conduct exhibitions, seminars, and competitions to spread awareness and curiosity about science. It also honors the contributions of scientists and motivates young minds to explore scientific careers. National Science Day fosters creativity, logical thinking, and a spirit of inquiry, helping build a scientifically aware and progressive nation.




Significance:

- Promotes scientific awareness among people
- Encourages innovation and research culture
- Inspires students to pursue science careers
- Highlights contributions of Indian scientists
- Strengthens national development through science
- Develops scientific temper in society



GNIPST GAME TIME



Identify the Drug Name

1. Who am I?

- I am a β -lactam antibiotic
- I inhibit bacterial cell wall synthesis
- I am commonly used for respiratory infections
- I may cause allergic reactions (rash, anaphylaxis)

2. Who am I?

- I am an antidiabetic drug
- I decrease hepatic glucose production
- I do not cause hypoglycemia when used alone
- I may cause lactic acidosis (rare but serious)

3. Who am I?

- I am an NSAID
- I inhibit cyclooxygenase (COX) enzyme
- I reduce pain, fever, and inflammation
- Long-term use may cause gastric ulcer

4. Who am I?

- I am a proton pump inhibitor
- I reduce gastric acid secretion
- I am used in peptic ulcer and GERD
- I act by inhibiting H^+/K^+ ATPase

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

or

CLICK
HERE

Celebrating the Achievers!



Suman Bhattacharjee
B. Pharm, 8th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology



Editor-in-Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamudra Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.linkedin.com



api.whatsapp.com

